Open Access

Prospective evaluation of probabilistic dose-escalated IMRT in prostate cancer

Daniel Wegener

Daniel Wegener

Department of Radiation Oncology, University Hospital TübingenTübingen, Germany
Search for this author on
Sciendo|Google Scholar
Wegener, Daniel
, 
Bernhard Berger

Bernhard Berger

Clinic for Radiation Oncology, St. Elisabethen-ClinicRavensburg, Germany
Search for this author on
Sciendo|Google Scholar
Berger, Bernhard
, 
Zhoulika Outtagarts

Zhoulika Outtagarts

Department of Radiation Oncology, University Hospital TübingenTübingen, Germany
Search for this author on
Sciendo|Google Scholar
Outtagarts, Zhoulika
, 
Daniel Zips

Daniel Zips

  • Department of Radiation Oncology, University Hospital TübingenTübingen, Germany
  • German Cancer Consortium (DKTK), Partner Site Tübingen; and German Cancer Research Center (DKFZ)Heidelberg, Germany
Search for this author on
Sciendo|Google Scholar
Zips, Daniel
, 
Frank Paulsen

Frank Paulsen

Department of Radiation Oncology, University Hospital TübingenTübingen, Germany
Search for this author on
Sciendo|Google Scholar
Paulsen, Frank
, 
Martin Bleif

Martin Bleif

Clinic for Radiology and Radiation Oncology, Alb Fils Clinic GöppingenGöppingen, Germany
Search for this author on
Sciendo|Google Scholar
Bleif, Martin
, 
Daniela Thorwarth

Daniela Thorwarth

Section for Biomedical Physics, Department of Radiation Oncology, University Hospital TübingenTübingen, Germany
Search for this author on
Sciendo|Google Scholar
Thorwarth, Daniela
, 
Markus Alber

Markus Alber

Clinic for Radiation Oncology, University Hospital HeidelbergHeidelberg, Germany
Search for this author on
Sciendo|Google Scholar
Alber, Markus
, 
Oliver Dohm

Oliver Dohm

Section for Biomedical Physics, Department of Radiation Oncology, University Hospital TübingenTübingen, Germany
Search for this author on
Sciendo|Google Scholar
Dohm, Oliver
 and 
Arndt-Christian Müller

Arndt-Christian Müller

Department of Radiation Oncology, University Hospital TübingenTübingen, Germany
Search for this author on
Sciendo|Google Scholar
Müller, Arndt-Christian
  
Dec 22, 2020
Prospective evaluation of probabilistic dose-escalated IMRT in prostate cancer's Cover Image
About this article
Previous Article
Next Article
Cite
Download Cover
Article Category: Research Article
Published Online: Dec 22, 2020
Page range: 88 - 96
Received: Aug 31, 2020
Accepted: Nov 02, 2020
DOI: https://doi.org/10.2478/raon-2020-0075
Keywords
© 2021 Daniel Wegener, Bernhard Berger, Zhoulika Outtagarts, Daniel Zips, Frank Paulsen, Martin Bleif, Daniela Thorwarth, Markus Alber, Oliver Dohm, Arndt-Christian Müller, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Figure 1

Coverage probability (CovP) concept: an example case is shown to indicate CovP-internal target volume (ITV) and planning organ at risk volumes (PRVs).
Coverage probability (CovP) concept: an example case is shown to indicate CovP-internal target volume (ITV) and planning organ at risk volumes (PRVs).

Figure 2

Survival outcomes: Kaplan-Meier curves of biochemically no evidence of disease (bNED), overall survival (OS), distant metastasis-free survival (DMFS) and prostate-cancer specific survival (PCSS).
Survival outcomes: Kaplan-Meier curves of biochemically no evidence of disease (bNED), overall survival (OS), distant metastasis-free survival (DMFS) and prostate-cancer specific survival (PCSS).

Figure 3

Late genitourinary (GU) toxicity items Radiation Therapy Oncology Group (RTOG) bladder late, common terminology criteria (CTC) urinary frequency and CTC urinary obstruction scored over the follow up (FU) period (left).Y-axis: percentage of patients reporting the toxicity item. Top X-axis: number n of patients with data available. Lower X-axis: years after radiotherapy. Right column: maximum late toxicity summed up by grade
Late genitourinary (GU) toxicity items Radiation Therapy Oncology Group (RTOG) bladder late, common terminology criteria (CTC) urinary frequency and CTC urinary obstruction scored over the follow up (FU) period (left).Y-axis: percentage of patients reporting the toxicity item. Top X-axis: number n of patients with data available. Lower X-axis: years after radiotherapy. Right column: maximum late toxicity summed up by grade

Figure 4

Late gastrointestinal (GI) toxicity items Radiation Therapy Oncology Group (RTOG) rectum late, common terminology criteria (CTC) proctitis and CTC rectal hemorrhage scored over the follow up (FU) period (left).Y-axis: percentage of patients reporting the toxicity item. Top X-axis: Number n of patients with data available. Lower X-axis: years after radiotherapy. Right column: maximum late toxicity summed up by grade.
Late gastrointestinal (GI) toxicity items Radiation Therapy Oncology Group (RTOG) rectum late, common terminology criteria (CTC) proctitis and CTC rectal hemorrhage scored over the follow up (FU) period (left).Y-axis: percentage of patients reporting the toxicity item. Top X-axis: Number n of patients with data available. Lower X-axis: years after radiotherapy. Right column: maximum late toxicity summed up by grade.

Patient characteristics of the study cohort

ParameterMean (min.- max.)Mediann (%)
Age at treatment (years)70 (56–83)70
Duration of radiotherapy (weeks)7.9 (7.4–8.7)7.9
Gleason-Score (n, %)
             64 (14.3 %)
             7a (3+4)15 (53.6 %)
             7b (4+3)9 (32.1 %)
cTNM (n, %)
             cT1c8 (28.6 %)
             cT2a8 (28.6 %)
             cT2b3 (10.7 %)
             cT2c9 (32.1 %)
Neoadjuvant ADT (n, %)22 (78.6 %)
             Duration of ADT (months, range)8.9 (3.0–27.0)6.0
             Initial PSA peak in ng/ml (range)9.1 (1.9–19.8)8.3
PSA-peak by subgroup
             0 < x ≤ 53 (10.7 %)
             5 < x ≤ 1015 (53.6 %)
             10 < x ≤ 158 (28.6 %)
             15 < x ≤ 202 (7.1 %)
Language:
English
Publication timeframe:
4 times per year
Journal Subjects:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology
Journal RSS Feed